A phase 1B/2A study to evaluate the effect of aerosolized, recombinant alpha 1-antitrypsin (rAAT) on epithelial lining fluid (ELF) analytes in subjects with AAT deficiency

D. Gelmont, D. Sundin, K. Chung (Westlake Village, Alameda, United States Of America)

Source: Annual Congress 2005 - COPD - treatment I
Session: COPD - treatment I
Session type: Thematic Poster Session
Number: 1919
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Gelmont, D. Sundin, K. Chung (Westlake Village, Alameda, United States Of America). A phase 1B/2A study to evaluate the effect of aerosolized, recombinant alpha 1-antitrypsin (rAAT) on epithelial lining fluid (ELF) analytes in subjects with AAT deficiency. Eur Respir J 2005; 26: Suppl. 49, 1919

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhalation of α 1-protease inhibitor (α 1-Pi): influence on the protease-antiprotease balance in the epithelial lining fluid (ELF) of patients with α 1-Pi deficiency
Source: Eur Respir J 2001; 18: Suppl. 33, 249s
Year: 2001

Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010



Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008


Phase I safety investigation of an aerosolized, recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 228s
Year: 2004

Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021


Inhibition of elastinolytic activity in induced sputum from COPD patients and healthy controls by recombinant alpha 1-antitrypsin (rAAT) and a fusion protein, TAPI
Source: Eur Respir J 2004; 24: Suppl. 48, 471s
Year: 2004

Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018


A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009


Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011


Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers.
Source: International Congress 2017 – New Mechanistic Findings in COPD
Year: 2017

Safety and efficacy of inhaled human α-1 antitrypsin (AAT) in cystic fibrosis: a report of a phase II clinical study
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009

Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003


Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007


Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study
Source: Eur Respir J 2005; 26: Suppl. 49, 361s
Year: 2005

Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency
Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Year: 2010

Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


Relationship between interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), C-reaktive protein (CRP), albumin (ALB) and alkaline phosphatase (ALP) in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 98s
Year: 2006

The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 260s
Year: 2002

Differences in nasal fluid levels of myeloperoxidase (MPO) and fucose after lavage with saline and histamine solutions, respectively, may indicate a neutrophil inflammation in the nasal mucosa in patients with COPD, and moreover, a glandular
Source: Eur Respir J 2002; 20: Suppl. 38, 93s
Year: 2002

Clara cell secretory protein (CC16) and surfactant protein D (SPD) in sputum supernatant in severe refractory asthma (SRA)
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012